Amryt Pharma Shares Tumble After FDA Rejects Oleogel-S10 Application

Shares of Amryt Pharma PLC fell more than 30% on Monday after the biopharmaceutical company said the U.S. Food and Drug Administration turned away its application seeking approval of Oleogel-S10 for the treatment of a rare, genetic skin disease.